H. Lundbeck A/S

FDA approves Rexulti (brexpiprazole) as adjunctive treatment for adults with major depressive disorder and as a treatment for adults with schizophrenia

Young adult patients* with schizophrenia show improved functioning and health-related quality of life with Abilify Maintena® (aripiprazole once-monthly) compared with paliperidone palmitate

Major shareholder announcement

Total number of voting rights and share capital in H. Lundbeck A/S as of 31 May 2015

Lundbeck increases its share capital by 186,676 shares (0.0950% of outstanding shares)

Solid performance in the first quarter of the year. Full year guidance maintained